Navigation Links
Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
Date:11/15/2011

terstitial pneumonitis or pulmonary fibrosis. Vectibix should not be administered in combination with oxaliplatin-containing chemotherapy to mCRC patients with mutant KRAS tumors or for whom KRAS tumor status is unknown.
  • Adverse events of special importance associated with Vectibix and/or EGFR monoclonal antibody therapies include dermatologic-related reactions, pulmonary complications, electrolyte disturbances, infusion-related reactions (including rare reports with fatal outcome) and ocular toxicities. Acute renal failure has been observed in patients who develop severe diarrhea and dehydration. These events should be monitored carefully, see Summary of Product Characteristics for information on appropriate management of these adverse events.
  • Vectibix should not be used in combination with IFL chemotherapy or in combination with bevacizumab containing chemotherapy. For patients with ECOG 2 performance status, assessment of benefit-risk is recommended prior to initiation of Vectibix in combination with chemotherapy for treatment of mCRC.

  • About Amgen

    Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    Forward-Looking Statements

    This news release contains forward-looking statements that a
    '/>"/>

    SOURCE Amgen Europe GmbH
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
    2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    3. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
    4. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
    5. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
    6. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
    7. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
    8. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
    9. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
    10. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
    11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... DALLAS , September 22, 2014 ... report "Cell Line Development Market by Product (Equipment, Media ... (Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, ... to 2019", published by MarketsandMarkets, analyzes and studies ... Browse 114 market data tables ...
    (Date:9/22/2014)... 2014 CytRx Corporation (Nasdaq: CYTR ... oncology, today announced that study designs and progress from ... a pivotal global Phase 3 clinical trial in relapsed/refractory ... clinical trial in small cell lung cancer, will be ... 2014 Congress being held September 26-30, in ...
    (Date:9/19/2014)... Sept. 19, 2014 Harwood Feffer LLP ( ... of directors of PDL BioPharma, Inc. ("PDL" or the ... board has breached its fiduciary duties to shareholders or ... 16, 2014, the Company disclosed: "On September 11, 2014, ... firm, Ernst & Young LLP ("EY"), that it was ...
    Breaking Medicine Technology:Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
    ... Feb. 23, 2011 Plexus Biomedical Inc. has been ... and Drug Administration to market the first device clinically ... Hemorrhoids associated with vaginal delivery are a frequent complication ... women in the U.S. every year. The ...
    ... Inc. (Nasdaq: MAPP ) today announced that the ... Citi,s 2011 Global Healthcare Conference , Wednesday, March 2, at ... , Thursday, March 3, at 10:00 a.m. ET in ... March 9, at 10:15 a.m. ET in BostonBarclays Capital 2011 ...
    Cached Medicine Technology:Plexus Biomedical Inc. Gains FDA Approval of the First Medical Device to Help Prevent External Hemorrhoids During Vaginal Childbirth 2
    (Date:9/22/2014)... 2014 Don Allred Insurance is pleased to ... Burlington, NC. The satellite office, located in the Holly Hill ... 15, 2014, and offer all of the same professional services ... Allred Insurance spokesperson Scott Allred cites an expanding client base ... two of the major factors driving the decision to open ...
    (Date:9/22/2014)... 22, 2014 Ethane Web Technologies, an ... to have announced affordable website redesign. The website redesign ... which are unsatisfied with their present websites and want ... to pay a big amount for this job. ... advanced tool, techniques, and experienced manpower so that it ...
    (Date:9/22/2014)... Colorado's grand experiment with legal recreational marijuana for adults ... revenue for the state. , According to the ... was sold in Colorado dispensaries during the first five ... , But the success of these retail shops has ... the thousands of consumers now seeking out cannabis dispensaries ...
    (Date:9/22/2014)... Available research evidence supports the use of deep ... who don,t respond to other treatments, concludes a review ... , official journal of the Congress of Neurological ... Lippincott Williams & Wilkins , a part of ... specific bilateral DBS techniques are recommended for treatment of ...
    (Date:9/22/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... GLOBAL MARKETS, the global market for autoimmune disease ... billion by 2019, with a five-year compound annual ... holds the highest market potential due to an ... western lifestyles. , In recent decades, autoimmune ...
    Breaking Medicine News(10 mins):Health News:Allred Insurance to Open New Burlington Branch Office 2Health News:Ethane Web Technologies Announces Affordable Website Redesign Service 2Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 2Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 3Health News:Evidence supports deep brain stimulation for obsessive-compulsive disorder 2Health News:Evidence supports deep brain stimulation for obsessive-compulsive disorder 3Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 3
    ... known about anticancer benefits of supplements, researchers caution , SUNDAY, ... may do nothing to protect men against bladder cancer and ... , In one study examining vitamin use, researchers analyzed more ... part in prostate screenings. , More than 60 percent ...
    ... 30 (HealthDay News) -- A study in mice suggests that ... scientists say. , Women may begin taking part in the ... added. , "We believe that this vaccine will someday be ... same way that vaccines have prevented many childhood diseases," principal ...
    ... just how sticking needles into the body can ease pain. ... Nature Neuroscience, a team at the University of Rochester ... in parlaying some of the effects of acupuncture in the ... the beneficial effects of acupuncture in mice by adding a ...
    ... ... $125 or more by FedEx Ground service to the 48 contiguous states in acknowledgment of ... allergy products company in the country, with over 10,000 referring doctors and 22 years of ... ...
    ... ... , ... Insurance Services, LLC ( HCCMIS ), is now utilizing CMN for health-care provider network administration in ...   Larger worldwide network directory with 400,000+ doctors and 7,000+ ...
    ... shallow or unfamiliar waters, experts say , SATURDAY, May 29 ... 14 are hospitalized each year because of a diving injury, ... spinal cord injury, researchers say. , To encourage diver safety, ... near any body of water and to jump feet first ...
    Cached Medicine News:Health News:Vitamins Fail to Protect Men Against Bladder Cancer 2Health News:Acupuncture's molecular effects pinned down 2Health News:National Allergy Supply Announces Free Ground Shipping For Its Customers 2Health News:HCC Medical Insurance Services Chooses CMN as Network Administrator 2Health News:Dive Safely -- Or Risk Spinal Cord Damage 2
    Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
    Cushing periosteal elevators, rounded edge, sharp, wide, blade width 5/8" (16 mm), length 7 1/4" (184 mm)....
    Barr periosteal elevators....
    Molt 9 periosteal elevators....
    Medicine Products: